계명대학교 의학도서관 Repository

Fimasartan-Based Blood Pressure Control after Acute Cerebral Ischemia: The Fimasartan-Based Blood Pressure Control after Acute Cerebral Ischemia Study

Metadata Downloads
Author(s)
Keun-Sik HongSun Uck KwonJong-Ho ParkJae-Kwan ChaJin-Man JungYong-Jae KimKyung Bok LeeSung Il SohnYong-Seok LeeJoung-Ho RhaJee-Hyun KwonSang Won HanBum Joon KimJaseong KooJay Chol ChoiSang Min SungSoo Joo LeeMan-Seok ParkSeong Hwan AhnOh Young BangYang-Ha HwangHyo Suk NamJong-Moo ParkHee-Joon BaeEung Gyu KimKyung-Yul LeeMi Sun Oh
Keimyung Author(s)
Sohn, Sung Il
Department
Dept. of Neurology (신경과학)
Journal Title
J Clin Neurol
Issued Date
2021
Volume
17
Issue
3
Keyword
blood pressureprevention and controlstrokefimasartan
Abstract
Background and Purpose:
Blood pressure (BP) control is strongly recommended, but BP control rate has not been well studied in patients with stroke. We evaluated the BP control rate with fimasartan-based antihypertensive therapy initiated in patients with recent cerebral ischemia.

Methods:
This multicenter, prospective, single-arm trial involved 27 centers in South Korea. Key inclusion criteria were recent cerebral ischemia within 90 days and high BP [systolic blood pressure (SBP) >140 mm Hg or diastolic blood pressure (DBP) >90 mm Hg]. BP lowering was initiated with fimasartan. BP management during the follow-up was at the discretion of the responsible investigators. The primary endpoint was the target BP goal achievement rate (<140/90 mm Hg) at 24 weeks. Key secondary endpoints included achieved BP and BP changes at each visit, and clinical events (ClinicalTrials.gov Identifier: NCT03231293).

Results:
Of 1,035 patients enrolled, 1,026 were included in the safety analysis, and 951 in the efficacy analysis. Their mean age was 64.1 years, 33% were female, the median time interval from onset to enrollment was 10 days, and the baseline SBP and DBP were 162.3±16.0 and 92.2±12.4 mm Hg (mean±SD). During the study period, 55.5% of patients were maintained on fimasartan monotherapy, and 44.5% received antihypertensive therapies other than fimasartan monotherapy at at least one visit. The target BP goal achievement rate at 24-week was 67.3% (48.6% at 4-week and 61.4% at 12-week). The mean BP was 139.0/81.8±18.3/11.7, 133.8/79.2±16.4/11.0, and 132.8/78.5±15.6/10.9 mm Hg at 4-, 12-, and 24-week. The treatment-emergent adverse event rate was 5.4%, including one serious adverse event.

Conclusions:
Fimasartan-based BP lowering achieved the target BP in two-thirds of patients at 24 weeks, and was generally well tolerated.
Keimyung Author(s)(Kor)
손성일
Publisher
School of Medicine (의과대학)
Citation
Keun-Sik Hong et al. (2021). Fimasartan-Based Blood Pressure Control after Acute Cerebral Ischemia: The Fimasartan-Based Blood Pressure Control after Acute Cerebral Ischemia Study. J Clin Neurol, 17(3), 344–353. doi: 10.3988/jcn.2021.17.3.344
Type
Article
ISSN
2005-5013
Source
https://www.thejcn.com/search.php?where=aview&id=10.3988/jcn.2021.17.3.344&code=0145JCN&vmode=FULL
DOI
10.3988/jcn.2021.17.3.344
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/43679
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Neurology (신경과학)
공개 및 라이선스
  • 공개 구분공개
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.